Ask the expert: Triple-negative breast cancer with Elaine Walsh, MB BCh BAO, PhD

general_content

Making up 15 to 20 percent of all breast cancer diagnoses, triple-negative breast cancer (TNBC) is often seen as a more aggressive subtype that disproportionally affects young, Black, and Latinx communities.

Oncologist Elaine Walsh, MB BCh BAO, PhD answers questions about TNBC symptoms, side-effects, and treatment options for early stage and metastatic breast cancer.

video

audio_embed

speakers_feature

About our expert

Elaine Walsh, MB BCh BAO, PhD

Elaine Walsh, MB BCh BAO, PhD, is a medical oncologist who specializes in the treatment of people with breast cancer. At Memorial Sloan Kettering Cancer Center, Dr. Walsh works as part of a multidisciplinary team to provide the highest level of care and best treatment options to people with breast cancer, while taking individual preferences and priorities into account.

3 Tier Sponsors

Event sponsors

upcoming_events

Upcoming Events

Navigating the changing landscape of early-stage breast cancer

Wed, May 14, 2025

Learn More

Newsflash: Updates from the 2025 ASCO Annual Meeting

Thu, Jun 12, 2025

Learn More

2025 Butterfly Ball

Sat, Nov 08, 2025

Learn More

View All Events View Past Events

related_resources_article_carousel

Related resources

Dealing with negative comments

01/23/25 | BY: Lisa Carey

Get tips on how to manage people who have opinions about your breast cancer treatment.

| 6 Min. Read | 2

Immunohistochemistry (IHC) tests

11/15/24 | BY: Regina Hampton

Some of the most important breast cancer treatment decisions are based on immunohistochemistry (IHC) tests; hormone receptor status, HER2 status, and in some cases, PD-L1 status.

| 7 Min. Read

Triple-negative

12/19/23 | BY: Reshma L. Mahtani

Triple-negative breast cancers (TNBC) test negative for hormone and HER2 receptors. About 10% to 15% of breast cancers are triple-negative.

| 13 Min. Read | 14

Triple-negative metastatic breast cancer

05/01/23 | BY: Rita Nanda

Metastatic triple-negative breast cancer is a rare form of aggressive breast cancer. Learn more its symptoms, diagnosis, and treatment options.

| 11 Min. Read | 3

Sacituzumab govitecan

02/03/23 | BY: Stephanie Graff

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with several types of metastatic breast cancer.

| 5 Min. Read | 11

Targeted therapy for triple-negative breast cancer

01/01/23 | BY: Zanetta Lamar

Learn more about the different classes of targeted therapies for triple-negative breast cancer, the tumor biomarkers that tell us who may benefit from them, and how they work.

| 4 Min. Read | 7

Follow-up care for TNBC

04/18/18 | BY: Lisa Carey

Learn what follow-up care may be needed and what it entails following a treatment for triple-negative breast cancer.

| 4 Min. Read | 9

Risks and fear of recurrence

04/18/18 | BY: Lisa Carey

Find out about activities and emotional support to help quell anxiety and worry after treatment for triple-negative breast cancer.

| 3 Min. Read